Abstract:Chemotherapy for brain glioma has been of limited benefit due to the inability of drugs to penetrate the blood brain barrier (BBB) and non-selective drug accumulation in the entire brain. To obviate these limitations, dual-targeting paclitaxel-loaded nanoparticles were developed by decoration with peptide-22 (PNP-PTX), a peptide with special affinity for low-density lipoprotein receptor (LDLR), to transport the drug across the BBB, and then target brain tumour cells. Enzyme-linked immune sorbent assay (ELISA) revealed that LDLR was over-expressed in C6 cells and brain capillary endothelial cells (BCECs), but low LDLR expression was observed in H92c(2-1) cells. Nanoparticle uptake demonstrated that peptide-22-decorated nanoparticles significantly increased the cellular uptake of nanoparticles by C6 cells and BCECs but not by H92c(2-1) cells, and excess free peptide-22 significantly inhibited the cellular uptake of PNP by C6 cells and BCECs. Cellular uptake mechanism experiments showed that PNP uptake by both BCECs and C6 cells was energy-dependant and caveolae- and clathrin-mediated endocytosis pathway other than macropinocytosis were involved. Dual-targeting effects in an in vitro BBB model showed that peptide-22 decoration on nanoparticles loaded with paclitaxel significantly increased the transport ratio of PTX across the BBB and induced apoptosis of C6 glioma cells below the BBB, and these effects were significantly inhibited by excess free peptide-22. Ex vivo and in vivo fluorescence imaging indicated that PNP labelled with a near-infrared dye could permeate the BBB and accumulate more in the glioma site than unmodified NP. Glioma section observed by fluorescence microscopy further demonstrated PNP distributed more extensively in both glioma bulk and infiltrative region around than unmodified NP. Pharmacodynamics results revealed that the median survival time of glioma-bearing mice administered with dual-targeting PNP PTX was significantly prolonged compared with that of any other group. TUNEL assay and H&E staining showed that PNP-PTX treatment induced significantly more cell apoptosis and tumour necrosis compared with other treatments. Taken together, these promising results suggested that the dual-targeting drug delivery system might have great potential for glioma therapy in clinical applications. (C) 2013 Elsevier Ltd. All rights reserved.

Aclarubicin‐loaded Cationic Albumin‐conjugated Pegylated Nanoparticle for Glioma Chemotherapy in Rats

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Data from Cationic Albumin–Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors Via Intravenous Administration

The Nanoparticle-Facilitated Autophagy Inhibition of Cancer Stem Cells for Improved Chemotherapeutic Effects on Glioblastomas

Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.

Fluorescent Bovine Serum Albumin-Silver Nanoclusters Loaded with Paclitaxel Can Traverse the Blood-Brain Barrier to Inhibit the Migration of Glioma

MCL1 Inhibitor Augmented the Anti‐Glioma Efficacy of Paclitaxel Utilizing a Multifunctional Cascade Nanodrug System

Polyethylene Glycol-Polylactic Acid Nanoparticles Modified with Cysteine-Arginine-glutamic Acid-Lysine-alanine Fibrin-Homing Peptide for Glioblastoma Therapy by Enhanced Retention Effect.

Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB

Ursolic Acid Nanoparticles for Glioblastoma Therapy

Substance P-modified Human Serum Albumin Nanoparticles Loaded with Paclitaxel for Targeted Therapy of Glioma

Anti-glioblastoma Efficacy and Safety of Paclitaxel-Loading Angiopep-conjugated Dual Targeting PEG-PCL Nanoparticles.

Ligand-Mediated and Enzyme-Directed Precise Targeting and Retention for the Enhanced Treatment of Glioblastoma

LDLR-mediated Peptide-22-conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma.

Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel.

Aptamer-functionalized PEG–PLGA Nanoparticles for Enhanced Anti-Glioma Drug Delivery

Radioiodine-labeled anti-epidermal growth factor receptor binding bovine serum albumin-polycaprolactone for targeting imaging of glioblastoma.

WITHDRAWN: Precise Engineering of Iguratimod and Rapamycin Drugs Loaded Polymeric Nanomaterials for the Treatment of Glioma Cancer Cells

RVG29-modified Docetaxel-Loaded Nanoparticles for Brain-Targeted Glioma Therapy